Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
CrCl mL/min; intermittent HD separate; continuous-HD data absent.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Qualitative label versus institutional intervals; exactly 20 overlaps
ANCOBON emphasizes concentration-guided adjustment without a renal interval table. UCSF supplies intervals, but its printed 20-40 and 10-20 bands both include 20.
What to reconcile: Clarify the boundary and dosing weight with ID/pharmacy; retain serum-level and toxicity monitoring.
UCSF Infectious Diseases Management Program · Adult oral flucytosine institutional schedule; concentration and toxicity monitoring remain necessary.
Renal method: CrCl mL/min; intermittent HD separate; continuous-HD data absent. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Use 25 mg/kg orally every 6 hours at CrCl >40; every 12 hours at 20-40; every 24 hours at 10-20; every 48 hours below 10. The printed ranges overlap at exactly 20: obtain clarification rather than rounding or choosing silently.
Intermittent HD: 25 mg/kg once now and after HD. Continuous HD: no data; consult ID pharmacy. The page lists ideal body weight, total weight if below ideal, and adjusted weight if >120% of ideal. Discuss doses exceeding 2000 mg with ID/antimicrobial stewardship.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.